Codexis Advances ECO Synthesis Platform Toward GMP Facility Build-Out and FDA Engagement in 2026

Codexis is moving its enzyme-driven siRNA manufacturing platform closer to GMP-scale production, a trajectory that carries direct implications for contract manufacturers and QA teams currently benchmarking solid-phase oligonucleotide synthesis (SPOS) against emerging enzymatic alternatives. The company reported $14.9 million in Q2 2026 revenue and reiterated full-year guidance, while outlining a facility and regulatory roadmap that extends through 2027.

At the TIDES US 2026 annual meeting in May, Codexis presented data showing its ECO Synthesis Manufacturing Platform achieves enzyme-driven stereoisomer control of siRNA compounds, a capability with direct relevance to product quality specifications and potency characterisation under current GMP frameworks. The company also demonstrated enzymatic RNA synthesis initiated from a single nucleotide and published comparative sustainability metrics against SPOS, the current industry standard. Interest from both emerging and established siRNA manufacturers followed.

On the capital side, Codexis closed an equity financing in July, generating approximately $25 million in net proceeds and bringing pro forma cash to roughly $80 million. That liquidity underpins the facility investment: the company is preparing a building permit application for its ECO GMP Manufacturing Center, with retrofit construction targeted for the second half of 2026 and full production capability planned by end of 2027. The stated purpose is supply of siRNA material for preclinical investigations and Phase 1 clinical trials, a scope that will require alignment with 21 CFR Part 211 and applicable ICH quality standards as the facility comes online.

For regulatory affairs leads, the more immediate checkpoint is a planned engagement with the FDA Emerging Technologies team in Q4 2026. Codexis has indicated the discussion will cover ECO Synthesis-derived siRNA product quality, stereoisomer control, and product comparability, topics that sit at the intersection of process validation and analytical method development for any CDMO considering platform adoption.

Financially, product gross margin held at 73% in Q2 2026 versus 72% in the prior-year period, driven by a mix shift toward higher-margin products. Total revenue declined modestly from $15.3 million in Q2 2025, attributed primarily to lower R&D revenue, partially offset by product revenue growth tied to customer product approvals and launches.

The Q4 2026 FDA meeting and the building permit submission represent the two near-term indicators that will signal whether ECO Synthesis is on track to compete with SPOS at commercial GMP scale by the end of 2027.

Source: Codexis, Inc. via GlobeNewswire press release, August 11, 2026.